Dabrafenib plus Trametinib Achieves Overall and Intracranial Responses [Clinical Trials]
Dabrafenib plus trametinib achieves intracranial responses in BRAF-mutant melanoma brain metastases. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Olaparib Keeps Hereditary Breast Tumors in Check [News in Brief]
In the phase III OlympiAD study, tumors shrank in about 60% of women with BRCA mutation–associated metastatic breast cancer who received the PARP inhibitor olaparib compared with 29% who received chemotherapy; the median time to disease progression was 7 months compared with 4.2 months, respectively. These findings are the first to demonstrate that a PARP inhibitor can improve progression-free survival in metastatic, hereditary breast cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Sending CAR T Cells After Multiple Myeloma [News in Brief]
Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/refractory disease. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Dacomitinib Beats Gefitinib for EGFR+ NSCLC [News in Brief]
The irreversible EGFR inhibitor dacomitinib reduced the chance of lung cancer progression compared with an older, first-generation EGFR inhibitor, gefitinib, in a phase III trial. As reported at the 2017 American Society of Clinical Oncology Annual Meeting, the experimental drug also increased toxicity, which could limit its use, especially with a safer, more effective third-generation EGFR inhibitor not far behind in the development pipeline. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma [News in Brief]
In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab—either alone or in combination with ipilimumab—posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. However, the combination, although more effective, was also more toxic. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Pan-Cancer Analysis Pinpoints Targets in PI3K Pathway [News in Brief]
A new study of all 32 cancer types in The Cancer Genome Atlas identifies genomic alterations that increase the activity of the PI3K/AKT/mTOR pathway. The study, which combines mutation data with measures of protein levels and phosphorylation status, suggests that mutations in IDH1, VHL, and STK11 promote activation of the pathway and may point to new drug targets. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Alectinib Superior to Crizotinib for ALK+ NSCLC [News in Brief]
Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer. Alectinib more than doubled progression-free survival, significantly reduced the incidence of brain and CNS metastases, and should be considered the new standard of care. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Treating ER+ Breast Cancer with CDK4/6 Inhibitors [News in Brief]
Data from the MONARCH2, PALOMA-1, and TREnd trials strongly support using CDK4/6 inhibitors alongside standard endocrine therapy for advanced ER-positive breast cancer. Including these targeted agents not only improves progression-free survival but may reverse acquired resistance to hormone treatment. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Targeting Nectin-4 in Bladder Cancer [News in Brief]
Preliminary findings from a phase I clinical trial indicate that enfortumab vedotin, an investigational antibody–drug conjugate targeting nectin-4, shows considerable efficacy in metastatic urothelial carcinoma. Robust responses were seen even among patients with disease progression on platinum chemotherapy and/or immune checkpoint blockade. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
FDA Partners with ASCO's CancerLinQ [News in Brief]
A partnership between the FDA and the American Society of Clinical Oncology's CancerLinQ provides regulators with timely, real-world data on newly approved cancer therapies. The alliance may help investigators gain insights and assess the impact of drugs in patient populations that are not well represented in traditional clinical trials. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Positive First Trial of Enasidenib for AML [News in Brief]
The first clinical trial of the investigational drug enasidenib, which targets IDH2 mutations, suggests that it is safe and may improve survival in patients with relapsed or refractory acute myeloid leukemia. It induced responses in 40.3% of patients, yielding a median overall survival of 9.3 months. (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma [Research Articles]
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Qamra, A., Xing, M., Padmanabhan, N., Kwok, J. J. T., Zhang, S., Xu, C., Leong, Y. S., Lee Lim, A. P., Tang, Q., Ooi, W. F., Suling Lin, J., Nandi, T., Yao, X., Ong, X., Lee, M., Tay, S. T., Keng, A. T. L., Gondo Santoso, E., Ng, C. C. Y., Ng, A., Jusakul Tags: Research Articles Source Type: research
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers [Research Articles]
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A., Wainberg, Z. A. Tags: Research Articles Source Type: research
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer [Research Articles]
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., Faris, J. E., Eskens, F. A. L. M., Sharma, S., Yaeger, R., Lenz, H.-J., Wainberg, Z. A., Avsar, E., Chatter Tags: Research Articles Source Type: research
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies [Research Articles]
This article is highlighted in the In This Issue feature, p. 539 (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Pa Tags: Research Articles Source Type: research
